WO2008102849A1 - Ｈｇｆ製剤 - Google Patents

Ｈｇｆ製剤 Download PDF

Info

Publication number
WO2008102849A1
WO2008102849A1 PCT/JP2008/052979 JP2008052979W WO2008102849A1 WO 2008102849 A1 WO2008102849 A1 WO 2008102849A1 JP 2008052979 W JP2008052979 W JP 2008052979W WO 2008102849 A1 WO2008102849 A1 WO 2008102849A1
Authority
WO
WIPO (PCT)
Prior art keywords
hgf
hgf preparation
preparation
disclosed
stored
Prior art date
Application number
PCT/JP2008/052979
Other languages
English (en)
French (fr)
Inventor
Kiichi Adachi
Keigo Hanada
Original Assignee
Kringle Pharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kringle Pharma Inc. filed Critical Kringle Pharma Inc.
Priority to KR1020097016540A priority Critical patent/KR101492511B1/ko
Priority to EP08711762.8A priority patent/EP2119449B1/en
Priority to JP2009500236A priority patent/JP5265514B2/ja
Priority to CA2675622A priority patent/CA2675622C/en
Publication of WO2008102849A1 publication Critical patent/WO2008102849A1/ja
Priority to US12/432,651 priority patent/US8461112B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

　本発明はＨＧＦおよび精製白糖を含有するＨＧＦ製剤である。本ＨＧＦ製剤は長期間の保存でも安定であるという特長を有する。
PCT/JP2008/052979 2007-02-22 2008-02-21 Ｈｇｆ製剤 WO2008102849A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020097016540A KR101492511B1 (ko) 2007-02-22 2008-02-21 Ｈｇｆ 제제
EP08711762.8A EP2119449B1 (en) 2007-02-22 2008-02-21 Hgf preparation
JP2009500236A JP5265514B2 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤
CA2675622A CA2675622C (en) 2007-02-22 2008-02-21 Hgf preparation
US12/432,651 US8461112B2 (en) 2007-02-22 2009-04-29 HGF preparation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/JP2007/053316 WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
JPPCT/JP2007/053316 2007-02-22

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 Continuation-In-Part WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
PCT/JP2007/053316 Continuation WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/432,651 Continuation US8461112B2 (en) 2007-02-22 2009-04-29 HGF preparation

Publications (1)

Publication Number Publication Date
WO2008102849A1 true WO2008102849A1 (ja) 2008-08-28

Family

ID=39709738

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤
PCT/JP2008/052979 WO2008102849A1 (ja) 2007-02-22 2008-02-21 Ｈｇｆ製剤

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/053316 WO2008102452A1 (ja) 2007-02-22 2007-02-22 Ｈｇｆ製剤

Country Status (6)

Country Link
US (1) US8461112B2 (ja)
EP (1) EP2119449B1 (ja)
KR (1) KR101492511B1 (ja)
CN (2) CN101578106A (ja)
CA (1) CA2675622C (ja)
WO (2) WO2008102452A1 (ja)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013511557A (ja) * 2009-11-23 2013-04-04 キュービスト ファーマシューティカルズ， インコーポレイテッド リポペプチド組成物および関連する方法
JP2015078177A (ja) * 2013-09-11 2015-04-23 第一三共株式会社 室温保存用凍結乾燥製剤
KR20160146736A (ko) 2014-04-28 2016-12-21 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆ의 동결건조 제제
US10213485B2 (en) 2014-09-10 2019-02-26 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
WO2021215375A1 (ja) 2020-04-20 2021-10-28 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
WO2022241465A1 (en) 2021-05-14 2022-11-17 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3170514A1 (en) 2020-03-12 2021-09-16 Baxter International Inc. Daptomycin formulations containing a combination of sorbitol and mannitol

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0925241A (ja) * 1995-07-11 1997-01-28 Snow Brand Milk Prod Co Ltd Ｈｇｆ凍結乾燥製剤
CN1579544A (zh) * 2003-08-09 2005-02-16 杨喜鸿 促肝细胞生长素口含片

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289628A (ja) * 1985-09-11 1987-04-24 Green Cross Corp:The 人フイブリノゲン製剤の加熱処理法
JP3680114B2 (ja) * 1993-09-17 2005-08-10 敏一 中村 脳神経障害治療剤
DE69838399T2 (de) 1997-12-03 2008-06-12 Nakamura, Toshikazu Präparation zur kontinuierlichen intravenösen verabreichung
AU5065599A (en) * 1998-08-05 2000-02-28 Sumitomo Pharmaceuticals Company, Limited Preparations for the administration of hepatocyte growth factor
US6896609B2 (en) * 2003-07-22 2005-05-24 International Truck Intellectual Property Company, Llc Driver/entry ventilation system for a bus
CN1554338A (zh) * 2003-12-23 2004-12-15 南京易川药物研究所 亚硫酸氢钠穿心莲内酯冻干制剂及其制备方法
EP1719521A1 (en) * 2004-01-30 2006-11-08 Mitsubishi Pharma Corporation Preventive and/or remedy for retinopathy
US7432044B2 (en) * 2004-07-26 2008-10-07 Genentech, Inc. Methods and compositions for modulating hepatocyte growth factor activation
CA2628928A1 (en) * 2005-11-10 2007-05-24 Receptor Biologix, Inc. Hepatocyte growth factor intron fusion proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0925241A (ja) * 1995-07-11 1997-01-28 Snow Brand Milk Prod Co Ltd Ｈｇｆ凍結乾燥製剤
CN1579544A (zh) * 2003-08-09 2005-02-16 杨喜鸿 促肝细胞生长素口含片

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARAKAWA T.: "Toketsu Sosa ni Oite Tenkabutsu wa Donoyoni shite Tanpakushitsu o Anteika surunoka", PROTEIN, NUCLEIC ACID AND ENZYME, vol. 37, no. 9, 1992, pages 1517 - 1523, XP003024526 *
See also references of EP2119449A4 *

Cited By (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9662397B2 (en) 2009-11-23 2017-05-30 Merck Sharp & Dohme Corp. Lipopeptide compositions and related methods
US9138456B2 (en) 2009-11-23 2015-09-22 Cubist Pharmaceuticals Llc Lipopeptide compositions and related methods
JP2016147874A (ja) * 2009-11-23 2016-08-18 キュービスト ファーマシューティカルズ リミテッド ライアビリティ カンパニー リポペプチド組成物および関連する方法
JP2013511557A (ja) * 2009-11-23 2013-04-04 キュービスト ファーマシューティカルズ， インコーポレイテッド リポペプチド組成物および関連する方法
JP2017075186A (ja) * 2009-11-23 2017-04-20 キュービスト ファーマシューティカルズ リミテッド ライアビリティ カンパニー リポペプチド組成物および関連する方法
JP2015078177A (ja) * 2013-09-11 2015-04-23 第一三共株式会社 室温保存用凍結乾燥製剤
KR20160146736A (ko) 2014-04-28 2016-12-21 에자이 알앤드디 매니지먼트 가부시키가이샤 Ｈｇｆ의 동결건조 제제
RU2693472C2 (ru) * 2014-04-28 2019-07-03 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лиофилизированный состав на основе hgf
US11547743B2 (en) 2014-04-28 2023-01-10 Eisai R&D Management Co., Ltd. Lyophilized formulation of HGF
US10213485B2 (en) 2014-09-10 2019-02-26 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
US10702582B2 (en) 2014-09-10 2020-07-07 Kringle Pharma Inc. HGF preparation suitable for treatment of neurological disorders
US11548926B2 (en) 2016-03-17 2023-01-10 Eisai R&D Management Co., Ltd. Method for producing an active hepatocyte growth factor (HGF)
WO2021215375A1 (ja) 2020-04-20 2021-10-28 塩野義製薬株式会社 Ｈｍｇｂ１部分ペプチドを含有する製剤
WO2022241465A1 (en) 2021-05-14 2022-11-17 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Also Published As

Publication number Publication date
CN103356995A (zh) 2013-10-23
EP2119449A4 (en) 2013-05-08
KR101492511B1 (ko) 2015-02-12
CN101578106A (zh) 2009-11-11
US8461112B2 (en) 2013-06-11
US20090233863A1 (en) 2009-09-17
WO2008102452A1 (ja) 2008-08-28
CA2675622C (en) 2015-10-06
KR20090118030A (ko) 2009-11-17
EP2119449B1 (en) 2014-09-03
CA2675622A1 (en) 2008-08-28
EP2119449A1 (en) 2009-11-18

Similar Documents

Publication Publication Date Title
WO2008102849A1 (ja) Ｈｇｆ製剤
EP1890746B8 (en) Injection device
EP2043711A4 (en) Automatic injection device
AU2006334372A8 (en) Cigarette substitute
AU2006100431A4 (en) 4Play Anti-Spiking Drink
AU2006904169A0 (en) Stable vein
AU2006901416A0 (en) Sequestering carbon dioxide
AU2006906325A0 (en) Ezi - feed highchair
AU2006905365A0 (en) Peg holder - square
AU2006906337A0 (en) An insertable side form
AU2006902936A0 (en) Automatic locking device
AU2006904644A0 (en) Ladder stabilising device
AU2007903645A0 (en) Adult toy
WO2008129157A3 (fr) Solution solide amorphe contenant un derive de pyrazole-3-carboxamide sous forme amorphe et des excipients stabilisateurs
AU2008902571A0 (en) Quik kick
AU2005903033A0 (en) Stopper
AU2006900155A0 (en) Safe point
AU2005100755A4 (en) Clearwater
AU2008100771A4 (en) School On Time
AU2006906791A0 (en) Chair stabilising device
AU2004900584A0 (en) C-Flex
AU2006902932A0 (en) Pourer insert
AU2006904165A0 (en) Child restraint
AU2006904238A0 (en) Fencing - Pipe End Post Design
AU314672S (en) Solid timber low line entertainment

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880001643.0

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08711762

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2675622

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020097016540

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2009500236

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008711762

Country of ref document: EP